10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Axxcess Wealth Management LLC boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 38.5% during ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.28% ...

Analyst Daniel Brennan of TD Cowen maintained a Hold rating on 10x Genomics (TXG – Research Report), retaining the price target of $18.00. Daniel Brennan has given his Hold rating due to a ...

10x Genomics ( (TXG)) has shared an update. 10x Genomics reported a slight decrease in third-quarter revenue to $151.7 million, primarily due to lower instrument sales, but noted strong ...

French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.28% ...

PLEASANTON, Calif. — PLEASANTON, Calif. — 10x Genomics Inc. (TXG) on Tuesday reported a loss of $35.8 million in its third quarter. On a per-share basis, the Pleasanton, California-based company said ...

10x Genomics (NASDAQ:TXG – Free Report) had its price target decreased by JPMorgan Chase & Co. from $20.00 to $14.00 in a ...

PARIS, Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc., a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics ...